Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients

Tang, Weili; Zhang, Feng; Liu, Ke; Duan, Xuanchu

doi:10.1097/md.0000000000016597

Cited by 52 publications

(39 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, the IOP decrease at 3 months after initiating or starting treatment was similar between groups, indicating a similar efficacy of the preserved and preservative-free formulations. The change in IOP is similar to previous publications of PCL [ 27 ]. Some have postulated that the disruption of the corneal epithelium by preservatives may allow greater therapeutic efficacy of topical ophthalmic medications [ 28 ].…”

Section: Discussionsupporting

confidence: 90%

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis

et al. 2021

View full text Add to dashboard Cite

Introduction To compare the tolerability and efficacy of a preservative-containing latanoprost (PCL) to a preservative-free formulation of latanoprost (PFL) in patients with open-angle glaucoma or ocular hypertension. Methods A pooled analysis was performed of data from five published studies. The primary outcome was tolerability as evaluated by the severity of hyperemia. The secondary objectives were patient tolerance based on a composite ocular surface disease (OSD) score arising from ocular signs and symptoms, patient and investigator satisfaction, and a comparison of IOP-lowering efficacy. Results There were three randomized controlled trials and two observational studies included in the analysis. Conjunctival hyperemia improved significantly in 25.6% (388) of patients switched to the PFL group versus 11.7% (117) of patients switched to the PCL group ( p < 0.001). PFL was two times superior to PCL in reducing ocular hyperemia (odds ratio = 1.96; p < 0.001). The mean OSD composite score decreased by 32.2% in patients switched to the PFL group and 14.1% in the PCL group ( p < 0.001). At 3 months, the mean IOP was similar between groups ( p = 0.312). Conclusion This post hoc pooled analysis confirmed the findings of the individual studies that PFL is as efficacious at reducing IOP as PCL but better tolerated. After switching to PFL, there was twice the improvement in the OSD composite score. PFL was twice as effective at reducing ocular hyperemia and other ocular signs. These findings suggest that PFL has features that may improve patient compliance, thereby potentially improving the IOP-lowering efficacy on a long-term basis.

show abstract

Section: Discussionsupporting

confidence: 90%

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…18,49 A recently published meta-analysis has shown that all prostaglandin analogues demonstrated a high incidence of conjunctival hyperemia. 53 Surprisingly, the data in this current study showed improvement of redness symptom, but the clinical sign of conjunctival hyperemia still unchanged. This may explain that the patients felt more comfortable after changing to preserved tafluprost and PF-tafluprost.…”

Section: Discussioncontrasting

confidence: 61%

<p>Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients</p>

Ruangvaravate

Choojun

Srikulsasitorn

et al. 2020

OPTH

View full text Add to dashboard Cite

To study ocular surface disease (OSD) changes after switching from preserved prostaglandin analogues monotherapy to preserved tafluprost and preservative-free (PF) tafluprost in primary open-angle glaucoma patients. Methods: Glaucoma patients treated with preserved prostaglandins (except tafluprost) monotherapy for at least 6 months, intraocular pressure (IOP) ≤22 mmHg, and diagnosed of OSD [≥1 criterion; tear break-up time (TBUT) ≤10 seconds, corneal fluorescein staining ≥grade 1] in both eyes were enrolled in a prospective, randomized, single-blinded study. All eligible patients were switched from preserved prostaglandin analogues monotherapy (latanoprost, bimatoprost, travoprost) to preserved tafluprost in one eye (group I) and PF-tafluprost in the other eye (group II) of the same patient by randomization. The symptoms of OSD were evaluated using the visual analogue scale, and lid inflammation, conjunctival hyperemia, TBUT, corneal fluorescein staining, and Schirmer I test were applied to assess the clinical signs. All parameters were evaluated before and then 6, 12, 24 weeks after switching the medications. Results: Thirty patients (80% women; mean age: 61.2 ±11.5 years) were included. Baseline parameters were not different between the treatment groups. After switching therapies, TBUT was significantly increased in both groups (p = 0.002, p = 0.004, respectively); however, group II had better tear quality. Other symptoms and clinical signs of OSD were improved and IOP was controlled in both groups. Conclusion: Treatment with PF-tafluprost improves TBUT better than preserved tafluprost, suggesting that PF-tafluprost should be especially beneficial for patients with pre-existing OSD. Less or no preservative anti-glaucoma eye drops can restore and enhance the ocular surface in glaucoma patients.

show abstract

“…It was recently reported that latanoprost eye drop causes cutaneous blistering rash of eyelids, the neck and dorsum of hands, which resolved with cessation of treatment [42]. A meta-analysis by Tang et al, observed that latanoprost was better tolerated compared to travoprost or bimatoprost [43]. Conjunctival hyperaemia occurs more frequently with bimatoprost and travoprost whereas more patients experienced growth of lashes compared to latanoprost.…”

Section: B) Adverse Effectsmentioning

confidence: 99%

Medical Management of Open-Angle Glaucoma: Focus on Mechanisms of Action and Adverse Drug Reactions

Razali¹,

Hassan²,

Bakar³

et al. 2021

JCHS

View full text Add to dashboard Cite

Glaucoma is an optic neuropathy characterised by optic nerve degeneration associated with visual field defects. It remains the world’s number one cause of irreversible blindness and patients usually present at late stage of the disease since it is generally asymptomatic until severe. The disease is subdivided into primary and secondary with primary open-angle glaucoma (POAG) being the most common type. At present, lowering the intraocular pressure (IOP) remains the only proven efficient approach in delaying the onset or preventing the progression of the disease. Medical treatment with topical antiglaucoma agents is the treatment of choice in open angle glaucoma. The use of antiglaucoma drugs aims to reduce IOP by enhancing aqueous humour (AH) outflow, reducing AH production, or both. The choice to use any available treatment option should be carefully considered in an attempt to maximise benefits and reducing the risk of developing adverse drug reactions. This review highlights the six classes of ocular hypotensive agents currently in use for POAG treatment including prostaglandin analogues; B-adrenergic receptor blockers; a-2 adrenergic receptor stimulants; carbonic anhydrase inhibitors; muscarinic receptor stimulants; rho kinase inhibitors with regards to their mechanism/s of action and potential adverse drug reactions, and antiglaucoma fixed drug combinations.

show abstract

Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients

Cited by 52 publications

References 37 publications

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis

<p>Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients</p>

Medical Management of Open-Angle Glaucoma: Focus on Mechanisms of Action and Adverse Drug Reactions

Contact Info

Product

Resources

About